- KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.Molecular oncology, 2020.
- Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancerGu Xiaobin; Tian Tian; Zhang Bo; Liu Yang; Yuan Chao; Shao Lijuan; Guo Yajun; Fan KexingTumor Biology, 2015, 36(4): 2651-2656.
- 23P Clinical utility of cell free DNA in pleural lavage and plasma in resectable NSCLC: A pilot studySaikia J.; Malik P.; Jain D.; Kumar S.; Bharati S.; Madan K.; Gamit P.; Deo S.V.S.; Kumar S.Journal of Thoracic Oncology, 2021, 16(4S).
期刊论文
Paradoxical prognostic phenomenon of plasma T-cell-derived circulating DNA level in advanced non-small cell lung cancer
22阅读
